Where does Vera Therapeutics's cash flow data come from?

Every line is extracted from Vera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Vera Therapeutics VERA Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$368.95M-23.1%	-$299.62M-18.9%	-$251.94M-15.4%	-$218.28M-24.4%	-$175.46M-15.3%
Depreciation and amortization	$523K+11.8%	$468K+20.6%	$388K+37.1%	$283K+58.1%	$179K+70.5%
Stock-based compensation	$43.39M+14.4%	$37.93M+14.3%	$33.18M+14.3%	$29.02M+18.8%	$24.42M+17.4%
Change in accounts payable	$4.35M-68.7%	$13.91M—	——	——	——
Change in accrued liabilities	$18.79M+30.1%	$14.44M—	——	——	——
Change in other assets	——	——	——	——	——
Non-cash operating lease expense	$1.11M-23.5%	$1.45M-23.1%	$1.88M-3.1%	$1.95M-2.9%	$2M-2.9%
Change in operating lease liabilities	-$1.27M+14.3%	-$1.48M+22.4%	-$1.91M+4.9%	-$2.01M+7.1%	-$2.16M+10.1%
Change in other current assets	——	——	——	-$487K-35.7%	-$359K-2.3%
Net cash from operating activities	-$293.2M-21.6%	-$241.1M-14.7%	-$210.29M-13.5%	-$185.27M-19.3%	-$155.26M-15.3%
Capital expenditures	$466K-26.0%	$630K-46.3%	$1.17M-8.2%	$1.28M+10.3%	$1.16M+19.2%
Net cash from investing activities	$41.15M-78.8%	$194.29M+280%	-$107.76M+39.3%	-$177.52M+22.4%	-$228.74M+50.6%
Repurchases of common stock	——	——	——	——	——
Proceeds from issuance of common stock	$9.39M+34.5%	$6.98M+36.7%	$5.11M+0.9%	$5.06M-37.0%	$8.04M-40.1%
Net cash from financing activities	$311.31M+0.8%	$308.9M-11.4%	$348.57M0.0%	$348.51M+5.1%	$331.67M-45.3%
Net increase (decrease) in cash	$59.26M-77.4%	$262.08M+759%	$30.52M+27.0%	$24.04M+272%	-$14.02M-130%
Interest paid	$6.77M+0.8%	$6.72M+0.8%	$6.67M+0.5%	$6.64M-1.1%	$6.71M+0.9%
Accretion Of Discount And Amortization Of Premium On Purchase Of Debt Securities	——	——	——	——	——
Accretion Of Loan Exit Fee And Amortization Of Loan Costs	——	——	——	——	$842K+4.0%
Operating lease liabilities	-$1.27M+14.3%	-$1.48M+22.4%	-$1.91M+4.9%	-$2.01M+7.1%	-$2.16M+10.1%
Increase (Decrease) in Other Current Assets	——	——	——	-$487K-35.7%	-$359K-2.3%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Operating lease right-of-use asset amortization	$1.11M-23.5%	$1.45M-23.1%	$1.88M-3.1%	$1.95M-2.9%	$2M-2.9%
Upfront And Milestone Obligations Under License Agreements	——	——	——	——	——
Purchase Of Internal Use Software License	——	——	——	——	——
Upfront And Milestone Payments Under License Agreements	——	——	——	——	——
Proceeds From Borrowings Net Of Costs	——	$0—	$0—	$0—	$0—
Proceeds from exercises of stock options and other stock issuances	$9.39M+34.5%	$6.98M+36.7%	$5.11M+0.9%	$5.06M-37.0%	$8.04M-40.1%
Cash Paid For Operating Leases	——	——	——	——	——
Increase Decrease In Operating Lease Liability	-$1.27M+14.3%	-$1.48M+22.4%	-$1.91M+4.9%	-$2.01M+7.1%	-$2.16M+10.1%
Purchases Of Property And Equipment Included In Accounts Payable	——	$252K+33.3%	$189K+50.0%	$126K+100%	$63K—
Receivable On Exercise Of Stock Options	——	——	——	——	——
Free cash flow	-$293.66M-21.5%	-$241.73M-14.3%	-$211.47M-13.4%	-$186.55M-19.3%	-$156.41M-15.3%
Free cash flow	-$293.66M-21.5%	-$241.73M-14.3%	-$211.47M-13.4%	-$186.55M-19.3%	-$156.41M-15.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Vera Therapeutics's cash flow data come from?: Every line is extracted from Vera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.